Corticotropin

DEA Class; Rx

Common Brand Names; H.P. Acthar Gel, Purified Cortrophin Gel

  • Corticosteroids

Parenteral adrenocorticotropic hormone (ACTH); highly purified and extracted from porcine pituitary glands
Repository injection primarily used in adults for multiple sclerosis; other corticosteroids usually preferred for other indications
In pediatric patients, repository injection primarily used for infantile spasms in infants and children less than 2 years

Indicated for the treatment of infantile spasms.

For the treatment of acute exacerbations of multiple sclerosis.
For the adjunctive treatment of an acute episode or exacerbation of rheumatoid arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), or ankylosing spondylitis.
For the treatment of symptomatic sarcoidosis.
For the treatment of ophthalmic diseases, such as keratitis, iritis, iridocyclitis, diffuse posterior uveitis, choroiditis, optic neuritis, chorioretinitis, and anterior segment inflammation.
For the induction of diuresis or remission of proteinuria in the nephrotic syndrome.
For the treatment of dermatologic and allergic states, including severe erythema multiforme, Stevens-Johnson syndrome, or serum sickness, or for collagen diseases such as systemic lupus erythematosus (SLE) or systemic dermatomyositis (polymyositis).
For the adjunctive treatment of an acute episode or exacerbation of psoriatic arthritis (PsA).

Sensitivity to porcine proteins

IV administration

Infants <2 years suspected of congenital infections

Coadministration of live or live-attenuated vaccines with immunosuppressive doses of corticotropin

Scleroderma

Osteoporosis

Systemic fungal infections

Ocular herpes simplex

Recent surgery

Active/history of peptic ulcer

CHF, HTN

Common

  • Edema, hypertension

  • Psychotic disorder

  • Disorder of skin

  • Hyperglycemia

  • Peptic ulcer disease

  • Immune hypersensitivity reaction

  • Muscle weakness

Serious

  • Cardiomegaly, congestive heart failure, necrotizing arteritis

  • Encephalitis due to human herpes simplex virus, relapse

  • Decreased body growth, Children

  • Pancreatitis

  • Thromboembolic disorder

  • Glaucoma

Increases susceptibility to new infection and risk of exacerbation, dissemination or reactivation of latent infections; signs and symptoms of infection may be masked

Adrenal insufficiency may occur after prolonged therapy; monitor for effects of hypothalamic-pituitary-axis suppression after stopping treatment

Cushing’s syndrome may occur after prolonged therapy; monitor for signs and symptoms

Elevated blood pressure, salt and water retention and hypokalemia may occur; monitor blood pressure and sodium and potassium levels

Do not administer live or live-attenuated vaccines to patients on immunosuppressive doses

May mask symptoms of other underlying disease/disorders; monitor patients for signs of other underlying disease/disorders that may be masked

Gastrointestinal perforation and bleeding may occur; there is a risk for gastric ulcers and bleeding; there is an increased risk of perforation in patients with certain GI disorders; signs and symptoms may be masked; monitor for signs of perforation and bleeding

Behavioral and mood disturbances may occur; may include euphoria, insomnia, mood swings, personality changes, severe depression, and psychosis; existing conditions may be aggravated; effects are reversible once therapy stopped

Symptoms of diabetes and myasthenia gravis may be worsened with treatment Monitor for cataracts, infections and glaucoma

In patients with hypothyroidism or liver cirrhosis, may result in an enhanced effect

Monitor pediatric patients on long term therapy for growth and physical development

Monitor for osteoporosis in patients on long term therapy

May have embryocidal effect in pregnancy; apprise women of potential harm to the fetus

Gel is immunogenic; limited available data suggest that a patient may develop antibodies to the gel after chronic administration and loss of endogenous ACTH and gel activity

Prolonged administration of the gel may increase risk of hypersensitivity reactions; cases of anaphylaxis have been reported in the postmarketing setting

Use in patients with sensitivity to porcine protein is contraindicated, and the possibility of sensitivity should be considered during the course of treatment should symptoms arise

Pregnancy Category: C

Lactation: excretion in milk unknown; use with caution

Adults

80 units/day subcutaneous or IM for most conditions; up to 120 units/day IM for multiple sclerosis exacerbations.

Geriatric

80 units/day subcutaneous or IM for most conditions; up to 120 units/day IM for multiple sclerosis exacerbations.

Adolescents

80 units/day subcutaneous or IM.

Children

2 years and older: 80 units/day subcutaneously or IM.
Less than 2 years: 150 units/m2/day IM.

Infants

150 units/m2/day IM.

Neonates

Safety and efficacy have not been established.

Corticotropin 

injectable solution

  • 80 units/mL

About the Author

You may also like these

0